Kuros Biosciences to Unveil 2023 Full Year Financial Results and Corporate Developments

Kuros Biosciences AG, a pioneering entity in bone graft technologies, has announced its plan to disclose its full-year financial outcomes and corporate progressions for the year 2023 on March 13, 2024. The Switzerland-based company aims to engage stakeholders through a video conference scheduled at 3pm CET/10am US EST subsequent to the announcement.

The announcement and forthcoming conference are part of Kuros Biosciences’ ongoing effort to maintain transparency and connectivity with its investors and partners. Registrations for the conference are currently open, allowing participants to secure their attendance in advance.

This move underscores the company’s commitment to advancing bone graft technologies and its dedication to sharing significant progress and financial health with its stakeholders. Kuros Biosciences continues to be a key player in biologic fusion technologies, with a broad presence across the United States, Switzerland, and the Netherlands.